AUTO-CHECK study: Molecular determinants of autoimmunity and immune related adverse events in advanced cancer patients treated with immune checkpoint inhibitors

Checkpoint inhibitors are a new and effective class of cancer treatment. Sometimes these drugs result in unpredictable and severe inflammatory side effects. We will apply techniques that have helped us understand autoimmune disease to investigate patients treated with checkpoint inhibitors, aiming to elucidate how individual genetic variation predisposes patients to side effects. If successful, this project will improve how these powerful drugs are prescribed and reduce the risk of toxicity.